PeptiDream Appoints Three New Executives to Strengthen Management System

PeptiDream Inc. (President and CEO: Patrick Reid, Headquarters: Kawasaki City, Kanagawa Prefecture, hereinafter "the Company") is pleased to announce the appointment of three new Executive Vice Presidents (EVP) today. By welcoming management talent with extensive experience in key positions at global biopharmaceutical companies to our leadership team, we will further strengthen our management system and drive continuous growth and transformation into a global drug discovery and development company.

The new leadership team will cover our core strategic areas, aiming to enhance operational execution, further expand our pipeline, and achieve long-term growth.

Comment from Patrick Reid, President and CEO of PeptiDream:

"I am extremely pleased to welcome three management professionals with outstanding experience and achievements to PeptiDream. Their expertise and leadership will play a crucial role as we continue to evolve into a global drug discovery and development company. With a strengthened management system, we will achieve efficient operations, scale up our business, and realize sustainable growth across our expanding clinical pipeline. I am confident that the new structure will be a significant step towards delivering long-term value to patients and stakeholders."

The following three individuals have joined the Company as new Executive Vice Presidents:

Kayori Ohura

Kayori Ohura, Executive Vice President: Operations

- Gained experience in all aspects of clinical development at Kyowa Hakko Kirin USA, then led the oversight of large global organizations and the advancement of global clinical development at Bristol Myers Squibb US headquarters. Subsequently, transferred to the Japanese subsidiary, where she served as an Executive Officer overseeing Asia Clinical Development Operations and Commercial Operations.

- Served as CEO of the Global Health Innovative Technology Fund (GHIT), promoting international public-private partnerships in global health.

- Led service and NGS (Next-Generation Sequencing) sales and operations in Japan as Representative Director, President & General Manager of Labcorp Japan and Representative Director, President & General Manager of Illumina K.K.

- Also serves as an Outside Director of Sugi Holdings.

Jun Kawano

Jun Kawano, Executive Vice President: Corporate Strategy

- Led the globalization of pharmaceutical business and regional operational leadership in the US and Europe at Astellas Pharma, and served as Head of Global Business Development.

- Most recently served as Executive Officer, Japan Commercial Head, leading sales strategy and operations in the Japanese market.

- Proven leadership in corporate strategy, business development, commercial, and global/regional operations at global pharmaceutical companies.

- Holds an MBA from the University of Chicago Booth School of Business.

Yukimichi Shikata

Yukimichi Shikata, Executive Vice President: People & Culture

- After a career as a researcher, including working as a Principal Scientist at the Neurology Unit London Research Laboratory at Eisai Co., Ltd., has extensive experience in human resources and talent development over many years.

- Most recently led the strengthening of organizational capabilities and global talent pool as General Manager of Global HR Strategy Promotion at Eisai Co., Ltd.

- Holds a Ph.D. from the Graduate School of Medicine, Okayama University.

These three individuals possess extensive experience in a wide range of fields, from drug discovery to global pharmaceutical development and sales, and will contribute to the advancement of our diverse pipeline and global expansion.

To support our continuous growth and transformation into a global drug discovery and development company, we have been strengthening our organizational structure. In addition to the Executive Leadership Team (ELT), we have newly established the Research Leadership Team (RLT) and Development Leadership Team (DLT) to enhance cross-departmental collaboration, improve operational efficiency, and strengthen decision-making and execution capabilities.

Furthermore, we have introduced a job title system of EVP, SVP, and VP, creating a highly scalable leadership structure that supports both the development of internal talent and the acquisition of external talent.

The participation of these three executives is part of this organizational reinforcement, further strengthening the new system and contributing to improved execution capabilities and sustainable growth in our expanding clinical pipeline.

About PeptiDream

PeptiDream Inc. (Tokyo Stock Exchange Prime Market, Securities Code: 4587) aims to improve the quality of life for people worldwide by addressing unmet medical needs through the creation of innovative new medicines from macrocyclic peptides. In the field of radiopharmaceuticals (RI), we sell radiopharmaceuticals in Japan through our wholly-owned subsidiary, PDR Pharma. Utilizing our proprietary drug discovery platform technology, PDPS (Peptide Discovery Platform System), we create innovative radiotherapeutic and radiodiagnostic agents and develop them as proprietary or partnered programs. In the Non-RI field, we are broadly advancing the development of peptide therapeutics, peptide-drug conjugates (PDCs), and multifunctional peptide complexes (MPCs) for therapeutic and diagnostic purposes using PDPS, building an extensive global network of collaborative R&D partners. PeptiDream is headquartered in Kawasaki City. For more information about our company, technologies, and pipeline, please visit https://www.peptidream.com.

[Contact for Inquiries Regarding This Release]

PeptiDream IR Public Relations: Okimoto

TEL: 044-223-6612

Email: [email protected]

Website: https://www.peptidream.com/

X: https://x.com/PeptiDream_Inc